Doyle Ramona 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Apr 22, 2021
Insider Transaction Report
Form 4
Doyle Ramona
Chief Medical Officer
Transactions
- Conversion
Stock Option (Right to Buy)
2021-04-20−750,000→ 0 totalExercise: $2.47Exp: 2030-12-30→ Common Stock (750,000 underlying) - Conversion
Stock Option (Right to Buy)
2021-04-20+750,000→ 750,000 totalExercise: $2.47Exp: 2030-12-30→ Class A Common Stock (750,000 underlying)
Footnotes (2)
- [F1]Twenty-Five percent (25%) of the shares subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
- [F2]Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO.